Amyvid 800 MBq/mL solution for injection
Sponsors
Glaxosmithkline Research & Development Limited, Acumen Pharmaceuticals Inc.
Conditions
Alzheimer's DiseaseEarly Alzheimer’s Disease (Mild Cognitive Impairment and
Mild Dementia Due to Alzheimer’s Disease)
Phase 2
A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared with Placebo in Patients with Early Alzheimer’s Disease
Active, not recruitingCTIS2023-505083-11-01
Start: 2024-05-07Target: 140Updated: 2025-12-04
A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheimer’s Disease
RecruitingCTIS2023-509807-34-00
Start: 2024-08-12Target: 175Updated: 2026-01-21